0000905718-18-000997.txt : 20181227 0000905718-18-000997.hdr.sgml : 20181227 20181227161228 ACCESSION NUMBER: 0000905718-18-000997 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181221 FILED AS OF DATE: 20181227 DATE AS OF CHANGE: 20181227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Abingworth LLP CENTRAL INDEX KEY: 0001397144 STATE OF INCORPORATION: X0 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 181254830 BUSINESS ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN BUSINESS PHONE: 44 (0)20 7534 1500 MAIL ADDRESS: STREET 1: 38 JERMYN STREET CITY: LONDON STATE: X0 ZIP: SW1Y 6DN ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1235 RADIO ROAD STREET 2: SUITE 110 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 1235 RADIO ROAD STREET 2: SUITE 110 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 3 1 soleno_fm3dec212018.xml X0206 3 2018-12-21 0 0001484565 SOLENO THERAPEUTICS INC SLNO 0001397144 Abingworth LLP 38 JERMYN STREET LONDON X0 SW1Y 6DN UNITED KINGDOM 0 0 1 0 Common Stock 4669272 I See Footnote Warrant 2.00 2018-12-21 2023-12-21 Common Stock $.001 par value 233463 I See Footnote Stock Option (right to buy) 1.57 2028-12-21 Common Stock $.001 par value 20000 I See Footnote The shares are held by Abingworth Bioventures VII, LP ("Abingworth"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth. ALLP holds the reported securities indirectly through Abingworth. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. These options (the "Options") were granted to Dr. Andrew Sinclair ("Sinclair"), a Partner of ALLP. ALLP provides advisory services to Abingworth. Under an agreement between Sinclair and ALLP, Sinclair is deemed to hold the Options and any shares of common stock issuable upon exercise of the Options for the benefit of ABV VII, and must exercise the Options solely upon the direction of ALLP. This option was granted on December 21, 2018 with respect to 20,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on December 21, 2018. /s/ John Heard 2018-12-27